Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update

Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic driver capable of initiating and maintaining the disease. Despite the remarkable efficacy of tyrosine kinase inhibitors (TK...

Descripción completa

Detalles Bibliográficos
Autores principales: Bavaro, Luana, Martelli, Margherita, Cavo, Michele, Soverini, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940932/
https://www.ncbi.nlm.nih.gov/pubmed/31817512
http://dx.doi.org/10.3390/ijms20246141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940932/
https://www.ncbi.nlm.nih.gov/pubmed/31817512
http://dx.doi.org/10.3390/ijms20246141

Ejemplares similares